Publication Topic

Heintz MM, Buerger AN, Haws LC, East AW, Cullen JM, Thompson CM. Comparison of phenotypic and transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and PPARα knockout mice. Abstract 3972, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025

Wikoff DS, Vincent MJ, Heintz MM, Pastula ST, Reichert H, Klaren WD, Haws LC. 2025. Application of a quantitative uncertainty assessment to develop ranges of plausible toxicity values when using observational data in risk assessment: A case study examining associations between PFOA and PFOS exposures and vaccine response. Toxicol Sci 204(1):96-115; doi: 10.1093/toxsci/kfae152. PMID: 39792025.

Lin HC, Sakolish C, Moyer HL, Carmichael PL, Baltazar MT, Ferguson SS, Stanko JP, Hewitt P, et al. 2024. An in vitro-in silico workflow for predicting renal clearance of PFAS. Toxicol Appl Pharmacol 489(Aug):117015; doi: 10.1016/j.taap.2024.117015. PMID: 38917890.

Kougias DG, Killius A, Collins J, Russman E, Maddaloni M. 2024. Per- and polyfluoroalkyl substances (PFAS) in drinking water: A retrospective case series with risk assessments. Chapter 7 in: Paustenbach DJ (ed), Human and Ecological Risk Assessment: Theory and Practice, Third Edition. Wiley, ISBN: 978-1-119-74296-8, pp. 337–396.

Covell LT, Donnell MT, Keeton KA, Madl AK. Human health risk assessment of per- and polyfluoroalkyl substances (PFAS) in facial cosmetics. Poster presentation P342 at Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024. In: The Toxicologist 198(Late-Breaking S1):233–234, Abstract 5240.

Lin H, Sakolish C, Moyer HL, Ferguson SS, Stanko JP, Carmichael PL, Hewitt P, Hoffmann S, et al. Predicting renal clearance of PFAS with a human kidney proximal tubule tissue chip and a novel physiologically-based kidney model. Abstract 3508, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Racz L, Gauthier A, Bare J, Heintz M, Feifarek D, Kennedy S, Panko J. 2024. Assessment of perfluorocarboxylic acids in fluorinated high-density polyethylene containers and estimation of potential non-cancer risks associated with anticipated use scenarios. Regul Toxicol Pharmacol 147(Feb):105560; doi: 10.1016/j.yrtph.2024.105560. PMID: 38182014.

Jacobellis M, Bain L, Baldwin W. Disruption of energy homeostasis by PFAS mixtures. Southeastern Society of Toxicology, University of Georgia, Athens, GA, 2023.

Rogers JM, Heintz MM, Thompson CM, Haws LC. 2023. A putative adverse outcome network for neonatal mortality and lower birth weight in rodents: Applicability to per- and polyfluoroalkyl substances and relevance to human health. Birth Defects Res 115(11)1011-1062; doi: 10.1002/bdr2.2185. PMID: 37219003.

Thompson CM, Heintz MM, Wolf JC, Cheru R, Haws LC, Cullen JM. 2023. Assessment of mouse liver histopathology following exposure to HFPO-DA with emphasis on understanding mechanisms of hepatocellular death. Toxicol Pathol 51(1–2):4–14; doi: 10.1177/01926233231159078. PMID: 36987989.

Heintz MM, Haws LC, Klaunig JE, Cullen JM, Thompson CM. 2023. Assessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans. Toxicol Sci 192(1):15–29; doi: 10.1093/toxic/kfad004. PMID: 36629480.

East A, Dawson DE, Brady S, Vallero DA, Tornero-Velez R. 2023. A scoping assessment of implemented toxicokinetic models of per- and polyfluoro-alkyl substances, with a focus on one-compartment models. Toxics 11(2):163; doi: 10.3390/toxics11020163. PMID: 36851038.

Heintz MM, Chappell GA, Thompson CM, Haws LC. 2022. Evaluation of transcriptomic responses in livers of mice exposed to the short-chain PFAS compound HFPO-DA. Front Toxicol 4(Jun 27):937168; doi: 10.3389/ftox.2022.937168. PMID: 35832492.

Lea IA, Pham LL, Antonijevic T, Thompson C, Borghoff SJ. 2022. Assessment of the applicability of the threshold of toxicological concern for per- and polyfluoroalkyl substances. Regul Toxicol Pharmacol 133(August):105190; doi: 10.1016/j.yrtph.2022.105190. PMID: 35662637.

Racz L. PFAS: How did we get here and where are we going? Keynote address at Alliance of Hazardous Materials Professionals national meeting, Las Vegas, NV, March 2022.

Hearon SE, Orr AA, Moyer H, Wang M, Tamamis P, Phillips TD. 2022. Montmorillonite clay-based sorbents decrease the bioavailability of per- and polyfluoralkyl substances (PFAS) from soil and their translocation to plants. Environ Res 205(Apr 1):112433; doi: 10.1016/j.envres.2021.112433. PMID: 34875259.

Rogers JM, Heintz MM, Thompson CM, Haws LC. Development of a putative adverse outcome pathway for neonatal mortality in rodents: Implications for human health risk assessments of PFAS. Poster presented at Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022.

Tornero-Velez R, Dawson D, East A, Breen M, Brady S, Vallero D, Hubal EC, Wambaugh, J. Using systematic evidence mapping to track the development of toxicokinetic models of PFAS from 2000–2021. Poster presented at Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022; doi: 10.23645/epacomptox.19333283.

Hearon SE, Orr AA, Moyer H, Wang M, Tamamis P, Phillips TD. Montmorillonite clay-based sorbents decrease the bioavailability of perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) from soil and their translocation to plants. Abstract 3113, Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022.

Kempisty DM, Racz L. 2021. Forever Chemicals: Environmental, Economic, and Social Equity Concerns with PFAS in the Environment. Routledge, Taylor and Francis Group; ISBN 9780367456405.